CSRP1

Summary

CSRP1 (cysteine and glycine rich protein 1, HGNC:2469) is a protein-coding gene on chromosome 1q32.1, encoding Cysteine and glycine-rich protein 1 (P21291). Could play a role in neuronal development.

This gene encodes a member of the cysteine-rich protein (CSRP) family. This gene family includes a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. The LIM/double zinc-finger motif found in this gene product occurs in proteins with critical functions in gene regulation, cell growth, and somatic differentiation. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 1465 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Disputed, ClinGen)
• Clinical variants (ClinVar): 51 total
• Druggable target: yes
• MANE Select transcript: NM_004078

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2469
Approved symbol	CSRP1
Name	cysteine and glycine rich protein 1
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	CSRP, D1S181E
Ensembl gene	ENSG00000159176
Ensembl biotype	protein_coding
OMIM	123876
Entrez	1465

Gene structure

Transcript identifiers

Ensembl transcripts: 31 — 20 protein_coding, 6 retained_intron, 5 protein_coding_CDS_not_defined

ENST00000340006, ENST00000367306, ENST00000458271, ENST00000471596, ENST00000481851, ENST00000524951, ENST00000526256, ENST00000526317, ENST00000526723, ENST00000527573, ENST00000527662, ENST00000529975, ENST00000530120, ENST00000531916, ENST00000532313, ENST00000532460, ENST00000533188, ENST00000533402, ENST00000533432, ENST00000905417, ENST00000905418, ENST00000905419, ENST00000905420, ENST00000905421, ENST00000905422, ENST00000905423, ENST00000905424, ENST00000905425, ENST00000905426, ENST00000915182, ENST00000967210

RefSeq mRNA: 4 — MANE Select: NM_004078 NM_001193570, NM_001193571, NM_001193572, NM_004078

CCDS: CCDS1413

Canonical transcript exons

ENST00000340006 — 6 exons

Exon	Start	End
ENSE00002195803	201507070	201507123
ENSE00003479163	201490176	201490344
ENSE00003600334	201488855	201488984
ENSE00003604532	201485283	201485376
ENSE00003653306	201496192	201496304
ENSE00003894071	201483530	201484789

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.87.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 187.6560 / max 3603.0848, expressed in 1776 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16673	184.1318	1772
16674	3.0375	1367
16671	0.4866	271

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
popliteal artery	UBERON:0002250	99.87	gold quality
tibial artery	UBERON:0007610	99.87	gold quality
lower esophagus	UBERON:0013473	99.85	gold quality
lower esophagus muscularis layer	UBERON:0035833	99.85	gold quality
right coronary artery	UBERON:0001625	99.84	gold quality
muscle layer of sigmoid colon	UBERON:0035805	99.84	gold quality
saphenous vein	UBERON:0007318	99.82	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.82	gold quality
body of uterus	UBERON:0009853	99.80	gold quality
aorta	UBERON:0000947	99.79	gold quality
left uterine tube	UBERON:0001303	99.79	gold quality
mucosa of stomach	UBERON:0001199	99.78	gold quality
cauda epididymis	UBERON:0004360	99.74	gold quality
smooth muscle tissue	UBERON:0001135	99.73	gold quality
left coronary artery	UBERON:0001626	99.73	gold quality
seminal vesicle	UBERON:0000998	99.71	gold quality
ascending aorta	UBERON:0001496	99.70	gold quality
thoracic aorta	UBERON:0001515	99.70	gold quality
coronary artery	UBERON:0001621	99.70	gold quality
blood vessel layer	UBERON:0004797	99.70	gold quality
myometrium	UBERON:0001296	99.65	gold quality
descending thoracic aorta	UBERON:0002345	99.63	gold quality
lateral globus pallidus	UBERON:0002476	99.63	gold quality
prostate gland	UBERON:0002367	99.55	gold quality
tibial nerve	UBERON:0001323	99.51	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.48	gold quality
endocervix	UBERON:0000458	99.45	gold quality
medial globus pallidus	UBERON:0002477	99.44	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.42	gold quality
globus pallidus	UBERON:0001875	99.39	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 9.

Experiment	Marker?	Max mean expression
E-MTAB-10287	yes	84.76
E-HCAD-1	yes	40.09
E-MTAB-8410	yes	33.24
E-GEOD-135922	yes	30.63
E-HCAD-11	yes	20.71
E-GEOD-84465	yes	12.64
E-CURD-46	yes	8.12
E-HCAD-9	yes	5.15
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CEBPA, CEBPB, HNF1A, MTF1, REL, SRF, STAT3

miRNA regulators (miRDB)

74 targeting CSRP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-378A-5P	99.65	66.33	1311
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-4651	99.06	67.57	2002
HSA-MIR-6749-3P	99.00	65.73	1443

Literature-anchored findings (GeneRIF, showing 7)

• Aberrant methylation of CSRP1 is associated with hepatocellular carcinoma (PMID:17341888)
• Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfite sequencing. (PMID:17486081)
• CRP1 expression is regulated by UVB in human keratinocytes, suggesting a role for CRP1 in the phototoxic responses of human skin. (PMID:20415737)
• Results show that CRP1 is a novel TGF-beta1 regulated protein that is expressed in fibrotic lesions and may be relevant in idiopathic pulmonary fibrosis. (PMID:21882188)
• A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. (PMID:22360420)
• Plasma ADMA is a useful parameter for predicting subclinical atherosclerosis, whereas homocysteine and hsCRP are not (PMID:24357092)
• CSRP1 Promotes Colon Adenocarcinoma Growth and Serves as an Independent Risk Biomarker for Worse Prognosis. (PMID:37113556)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	csrp1a	ENSDARG00000006603
danio_rerio	csrp1b	ENSDARG00000030980
mus_musculus	Csrp1	ENSMUSG00000026421
rattus_norvegicus	Csrp1	ENSRNOG00000008937
drosophila_melanogaster	Mlp84B	FBGN0014863
drosophila_melanogaster	Mlp60A	FBGN0259209
caenorhabditis_elegans		WBGENE00003375

Paralogs (2): CSRP3 (ENSG00000129170), CSRP2 (ENSG00000175183)

Protein

Protein identifiers

Cysteine and glycine-rich protein 1 — P21291 (reviewed: P21291)

Alternative names: Cysteine-rich protein 1, Epididymis luminal protein 141

All UniProt accessions (7): P21291, A0A087X134, A0A384P5K2, B4DY28, E9PND2, E9PP21, E9PS42

UniProt curated annotations — full annotation on UniProt →

Function. Could play a role in neuronal development.

Subunit / interactions. Interacts with ASCC1; ASCC2 and TRIP4.

Subcellular location. Nucleus.

RefSeq proteins (4): NP_001180499, NP_001180500, NP_001180501, NP_004069* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001781	Znf_LIM	Domain

Pfam: PF00412

UniProt features (14 total): modified residue 7, domain 2, chain 1, cross-link 1, sequence variant 1, sequence conflict 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P21291-F1	72.49	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 192, 91, 81, 84, 112, 131, 137, 161

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5660489	MTF1 activates gene expression

MSigDB gene sets: 255 (showing top): GOBP_MUSCLE_TISSUE_DEVELOPMENT, ENK_UV_RESPONSE_KERATINOCYTE_UP, GOBP_PLATELET_ACTIVATION, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOBP_STRIATED_MUSCLE_CELL_DIFFERENTIATION, GOBP_SARCOMERE_ORGANIZATION, BOYLAN_MULTIPLE_MYELOMA_D_DN, SRF_Q5_01, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN

GO Biological Process (3): sarcomere organization (GO:0045214), muscle tissue development (GO:0060537), platelet aggregation (GO:0070527)

GO Molecular Function (6): RNA binding (GO:0003723), zinc ion binding (GO:0008270), structural constituent of muscle (GO:0008307), actinin binding (GO:0042805), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), focal adhesion (GO:0005925), Z disc (GO:0030018), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Response to metal ions	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
myofibril assembly	1
actomyosin structure organization	1
tissue development	1
platelet activation	1
homotypic cell-cell adhesion	1
nucleic acid binding	1
transition metal ion binding	1
structural molecule activity	1
cytoskeletal protein binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cell-substrate junction	1
I band	1
extracellular vesicle	1

Protein interactions and networks

STRING

1070 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSRP1	MED14	O60244	718
CSRP1	LMO1	P25800	717
CSRP1	ZYX	Q15942	656
CSRP1	MYOG	P15173	633
CSRP1	SPARC	P09486	612
CSRP1	LMO2	P25791	558
CSRP1	ISL1	P20663	507
CSRP1	ENO1	P06733	474
CSRP1	ANXA2	P07355	448
CSRP1	AHNAK	Q09666	446
CSRP1	DPYSL2	Q16555	442
CSRP1	SH3BGRL3	Q9H299	437
CSRP1	GAPDH	P00354	437
CSRP1	ASB9	Q96DX5	435
CSRP1	S100A6	P06703	423

IntAct

36 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CSRP1	CA9	psi-mi:“MI:0915”(physical association)	0.560
CSRP1	REEP1	psi-mi:“MI:0915”(physical association)	0.560
EGFR	CSRP1	psi-mi:“MI:0915”(physical association)	0.550
GRB2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
CSRP1	ESR1	psi-mi:“MI:0915”(physical association)	0.370
	E2F3	psi-mi:“MI:0914”(association)	0.350
SPHK1	MYO1C	psi-mi:“MI:0914”(association)	0.350
BCAR1	PSMD11	psi-mi:“MI:0914”(association)	0.350
BCAR1	MYO1C	psi-mi:“MI:0914”(association)	0.350
	BANF1	psi-mi:“MI:0914”(association)	0.350
PTCHD1	DDX3X	psi-mi:“MI:0914”(association)	0.350
	PIK3C2A	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
HSPA8	AGPS	psi-mi:“MI:0914”(association)	0.350
B3GNT2	PDLIM1	psi-mi:“MI:0914”(association)	0.350
SLC11A2	UBXN8	psi-mi:“MI:0914”(association)	0.350
SLC39A12	ESYT2	psi-mi:“MI:0914”(association)	0.350
CREB1	ACOT7	psi-mi:“MI:0914”(association)	0.350
CNTRL	ANKRD28	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (82): CSRP1 (Affinity Capture-MS), CSRP1 (Affinity Capture-MS), CSRP1 (Affinity Capture-MS), CSRP1 (Co-fractionation), CSRP1 (Co-fractionation), CSRP1 (Co-fractionation), CSRP1 (Co-fractionation), CSRP1 (Co-fractionation), FUBP3 (Co-fractionation), TALDO1 (Co-fractionation), CSRP1 (Two-hybrid), CSRP1 (Proximity Label-MS), CSRP1 (Affinity Capture-Western), CSRP1 (Affinity Capture-Western), CSRP1 (Affinity Capture-Western)

ESM2 similar proteins: O00151, O04193, O35115, O70400, O70433, O80839, P21291, P29675, P36201, P47875, P50238, P50461, P50462, P50463, P50464, P52943, P52944, P53777, P63254, P63255, P67966, P67967, P97315, Q0VFX8, Q14192, Q16527, Q1ECF5, Q1LZA7, Q24400, Q2KI95, Q3MHY1, Q4KM31, Q4U0T9, Q500W4, Q56K04, Q5E9E1, Q5R7Y1, Q5RCT4, Q5RGJ5, Q5ZLR4

Diamond homologs: B0KYV5, D4A1F2, F1LR10, F1MF74, F1QH17, F1QWK4, F1RA39, F6QZ15, G3MWR8, G5EF51, O04193, O60952, O77506, O80839, O94851, P21291, P29675, P36201, P47875, P50460, P50461, P50462, P50463, P52943, P53777, P67966, P67967, P97314, P97315, Q05158, Q0E908, Q0VFX8, Q14847, Q16527, Q1ECF5, Q1LZA7, Q32LE9, Q3B7M5, Q3MHY1, Q4KM31

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CEBPB	“up-regulates quantity by expression”	CSRP1	“transcriptional regulation”
REL	“up-regulates quantity by expression”	CSRP1	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Clathrin-mediated endocytosis	5	15.2×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1037 predictions. Top by Δscore:

Variant	Effect	Δscore
1:201485278:CCCA:C	donor_loss	1.0000
1:201485280:CA:C	donor_loss	1.0000
1:201485372:CAGGA:C	acceptor_gain	1.0000
1:201485373:AGGA:A	acceptor_gain	1.0000
1:201485374:GGA:G	acceptor_gain	1.0000
1:201485375:GA:G	acceptor_gain	1.0000
1:201485375:GACTA:G	acceptor_loss	1.0000
1:201485376:AC:A	acceptor_loss	1.0000
1:201485377:C:CC	acceptor_gain	1.0000
1:201485377:C:T	acceptor_loss	1.0000
1:201485378:T:C	acceptor_loss	1.0000
1:201485382:C:CT	acceptor_gain	1.0000
1:201486938:A:AC	donor_gain	1.0000
1:201488985:C:CC	acceptor_gain	1.0000
1:201490169:TAC:T	donor_loss	1.0000
1:201490170:A:AC	donor_gain	1.0000
1:201490170:AC:A	donor_loss	1.0000
1:201490171:C:CC	donor_gain	1.0000
1:201490171:CTCA:C	donor_gain	1.0000
1:201490172:TCA:T	donor_loss	1.0000
1:201490173:CA:C	donor_loss	1.0000
1:201490174:A:AC	donor_gain	1.0000
1:201490174:ACT:A	donor_gain	1.0000
1:201490174:ACTC:A	donor_gain	1.0000
1:201490175:C:CT	donor_gain	1.0000
1:201490175:CT:C	donor_gain	1.0000
1:201490175:CTC:C	donor_gain	1.0000
1:201490175:CTCC:C	donor_gain	1.0000
1:201490175:CTCCT:C	donor_gain	1.0000
1:201490342:CCA:C	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000037925 (1:201492219 T>C), RS1000091437 (1:201500439 G>A), RS1000106423 (1:201486128 G>T), RS1000191763 (1:201494026 G>A), RS1000388937 (1:201491948 T>C), RS1000470467 (1:201500213 G>A), RS1000525977 (1:201508166 C>T), RS1000580051 (1:201508429 G>A), RS1000641714 (1:201505934 A>C), RS1000737434 (1:201502024 T>G), RS1000802074 (1:201503341 T>C), RS1001183808 (1:201502655 C>A,T), RS1001291431 (1:201497430 G>A), RS1001445531 (1:201491217 G>A), RS1001635076 (1:201502956 G>A)

Disease associations

OMIM: gene MIM:123876 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Disputed Evidence	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Disputed	AD

Mondo (1): congenital heart disease (MONDO:0005453)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295728 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

79 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases methylation	6
trichostatin A	affects cotreatment, increases expression	3
bisphenol A	affects expression, decreases expression	2
sodium arsenite	increases expression	2
cobaltous chloride	decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression, affects cotreatment	2
Cisplatin	affects cotreatment, decreases expression, increases expression	2
Doxorubicin	affects expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silver	increases expression	2
Smoke	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	increases expression	2
Particulate Matter	affects cotreatment, increases abundance, increases expression, decreases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
2,4,6-tribromophenol	decreases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
lead acetate	increases expression	1
methylselenic acid	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
artenimol	affects binding	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118648	Binding	Binding affinity to CSRP1 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1PH	Abcam HeLa CSRP1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE